Tag
This article examines the prevalent coprescription of enzyme-inducing antiseizure medications (ASMs) and susceptible hormonal contraceptives among US Medicaid beneficiaries with epilepsy, highlighting patient risk factors and implications f
This review synthesizes evidence on paternal valproate exposure and offspring neurodevelopmental risks, highlighting recent large cohort data that challenge prior concerns of increased neurodevelopmental disorders or congenital malformation
This study reveals distinct thromboembolic, bleeding, and mortality risks based on antiseizure medication selection in epilepsy patients receiving direct oral anticoagulants, highlighting the critical role of ASM choice on patient safety an
A large multicenter real-world study indicates that cenobamate provides superior effectiveness and seizure freedom rates compared to brivaracetam, lacosamide, and perampanel in adults with drug-resistant focal epilepsy, despite a higher inc
The HEP2 prospective cohort shows that most patients with focal treatment‑resistant epilepsy experienced substantial seizure reductions over 18–36 months; ASM additions produced modest gains but rarely achieved freedom, and device-treated p
New data reveal many patients with focal epilepsy experience seizures beyond the first treatment year, with nearly a quarter developing resistance to antiseizure medications, underscoring the need for optimized treatment strategies.
A decade-long French study reveals declining prenatal exposure to high-risk antiseizure drugs, increased use of safer alternatives, and a notable rise in prescriptions for newer drugs with uncertain safety profiles.
